当前位置： SCI文献检索 > MOLECULAR CANCER THERAPEUTICS期刊下所有文献 > Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers.

Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers.

Abstract：

:Molecular profiling of markers involved in the activity of chemotherapeutic agents can shed light on the successes and failures of treatment in patients and can also provide a basis for individualization of therapy. Toward those ends, we have used reverse-phase protein lysate microarrays to evaluate expression of protein components of the nucleotide excision repair (NER) pathways. Those pathways strongly influence the anticancer activities of numerous drugs, including those that are the focus here, cisplatin and ecteinascidin 743 (Et-743; Yondelis, Trabectedin). Cisplatin is generally more active in cell types deficient in NER, whereas Et-743 tends to be less active in those cells. We measured protein expression and sensitivity to those drugs in 17 human ovarian and colon cancer cell lines (13 of them from the NCI-60 panel) and five xeroderma pigmentosum (XP) patient cell types, each containing a different NER defect. Of the NER proteins giving reliable signals, XPF and XPG showed the highest correlations of protein expression with drug activity across all three tissue-of-origin groups. When we compared protein expression data with mRNA expression data from Affymetrix U133A chips, we found no consistent correlation between the two across the cell lines studied, which reinforces the conclusion that protein measurements can give more interpretable mechanistic information than can transcript measurements. The work reported here provides motivation for larger proteomic studies with more cell types focused on potential biomarkers in additional pharmacologically pertinent pathways.

journal_name

Mol Cancer Ther

journal_title

Molecular cancer therapeutics

authors

Stevens EV,Nishizuka S,Antony S,Reimers M,Varma S,Young L,Munson PJ,Weinstein JN,Kohn EC,Pommier Y

doi

10.1158/1535-7163.MCT-07-0192

subject

Has Abstract

pub_date

2008-01-01 00:00:00

pages

10-8

issue

1

eissn

1535-7163

issn

1538-8514

pii

1535-7163.MCT-07-0192

journal_volume

7

pub_type

杂志文章

相关文献

MOLECULAR CANCER THERAPEUTICS文献大全
  • PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

    abstract：:PHA-739358 is a small-molecule 3-aminopyrazole derivative with strong activity against Aurora kinases and cross-reactivities with some receptor tyrosine kinases relevant for cancer. PHA-739358 inhibits all Aurora kinase family members and shows a dominant Aurora B kinase inhibition-related cellular phenotype and mecha...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-07-0444

    authors： Carpinelli P,Ceruti R,Giorgini ML,Cappella P,Gianellini L,Croci V,Degrassi A,Texido G,Rocchetti M,Vianello P,Rusconi L,Storici P,Zugnoni P,Arrigoni C,Soncini C,Alli C,Patton V,Marsiglio A,Ballinari D,Pesenti E,Fan

    更新日期：2007-12-01 00:00:00

  • An optical probe for noninvasive molecular imaging of orthotopic brain tumors overexpressing epidermal growth factor receptor.

    abstract：:We have developed a near-infrared (NIR) probe that targets cells overexpressing the EGF receptor (EGFR) for imaging glioblastoma brain tumors in live subjects. A peptide specific for the EGFR was modified with various lengths of monodiscrete polyethylene glycol (PEG) units and a NIR Cy5.5 fluorescence dye. The lead co...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-12-0211

    authors： Agnes RS,Broome AM,Wang J,Verma A,Lavik K,Basilion JP

    更新日期：2012-10-01 00:00:00

  • Enterolactone inhibits the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in the rat.

    abstract：:The inverse association between a high enterolactone (ENL) concentration in both urine and serum, and the risk of breast cancer found in epidemiological studies suggests a chemopreventive action for ENL. However, no causal relationship has been established in clinical studies or in experimental models for breast cance...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Saarinen NM,Huovinen R,Wärri A,Mäkelä SI,Valentín-Blasini L,Sjöholm R,Ammälä J,Lehtilä R,Eckerman C,Collan YU,Santti RS

    更新日期：2002-08-01 00:00:00

  • Therapeutic targeting of angiogenesis with a recombinant CTT peptide-endostatin mimic-kringle 5 protein.

    abstract：:Angiogenesis is required for tumor growth and metastasis, and targeting angiogenesis is a novel anticancer strategy. However, cancer development is a complex multistep process, and single antiangiogenic agents have limited therapeutic efficacy. Here, we report a triple fusion protein, namely CTT peptide-endostatin mim...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-14-0266

    authors： Wang H,Yang Z,Gu J

    更新日期：2014-11-01 00:00:00

  • Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.

    abstract：:To determine the efficacy of a novel and safer (for gastrointestinal tract) aspirin (aspirin-PC) in preclinical models of ovarian cancer, in vitro dose-response studies were performed to compare the growth-inhibitory effect of aspirin-PC versus aspirin on three human (A2780, SKOV3ip1, and HeyA8) and a mouse (ID8) ovar...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-16-0074

    authors： Huang Y,Lichtenberger LM,Taylor M,Bottsford-Miller JN,Haemmerle M,Wagner MJ,Lyons Y,Pradeep S,Hu W,Previs RA,Hansen JM,Fang D,Dorniak PL,Filant J,Dial EJ,Shen F,Hatakeyama H,Sood AK

    更新日期：2016-12-01 00:00:00

  • Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.

    abstract：:IPI-504 is a novel, highly soluble small-molecule inhibitor of heat shock protein 90 (Hsp90), a protein chaperone essential for regulating homeostasis of oncoproteins and cell signaling proteins. Human epidermal growth factor receptor 2 (HER2; ErbB2) oncoprotein, expressed in a subset of metastatic breast cancers, is ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-08-1038

    authors： Leow CC,Chesebrough J,Coffman KT,Fazenbaker CA,Gooya J,Weng D,Coats S,Jackson D,Jallal B,Chang Y

    更新日期：2009-08-01 00:00:00

  • Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus.

    abstract：:The cytosine analogue decitabine alters hematopoietic differentiation. For example, decitabine treatment increases self-renewal of normal hematopoietic stem cells. The mechanisms underlying decitabine-induced shifts in differentiation are poorly understood, but likely relate to the ability of decitabine to deplete the...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-10-0191

    authors： Hu Z,Negrotto S,Gu X,Mahfouz R,Ng KP,Ebrahem Q,Copelan E,Singh H,Maciejewski JP,Saunthararajah Y

    更新日期：2010-06-01 00:00:00

  • Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.

    abstract：:The PI3K/AKT/mTOR pathway, which is aberrantly stimulated in many cancer cells, has emerged as a target for therapy. However, mTORC1/S6K also mediates negative feedback loops that attenuate upstream signaling. Suppression of these feedback loops opposes the growth-suppressive effects of mTOR inhibitors and leads to dr...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-14-0669

    authors： Soares HP,Ming M,Mellon M,Young SH,Han L,Sinnet-Smith J,Rozengurt E

    更新日期：2015-04-01 00:00:00

  • The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.

    abstract：:p53 is a critical tumor suppressor and is the most frequently inactivated gene in human cancer. Inhibition of the interaction of p53 with its negative regulator MDM2 represents a promising clinical strategy to treat p53 wild-type tumors. AMG 232 is a potential best-in-class inhibitor of the MDM2-p53 interaction and is...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-14-0710

    authors： Canon J,Osgood T,Olson SH,Saiki AY,Robertson R,Yu D,Eksterowicz J,Ye Q,Jin L,Chen A,Zhou J,Cordover D,Kaufman S,Kendall R,Oliner JD,Coxon A,Radinsky R

    更新日期：2015-03-01 00:00:00

  • Cell Death Induced by Cationic Amphiphilic Drugs Depends on Lysosomal Ca2+ Release and Cyclic AMP.

    abstract：:Repurposing cationic amphiphilic drugs (CAD) for cancer treatment is emerging as an attractive means to enhance the efficacy of chemotherapy. Many commonly used CADs, including several cation amphiphilic antihistamines and antidepressants, induce cancer-specific, lysosome-dependent cell death and sensitize cancer cell...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-18-1406

    authors： Anand A,Liu B,Dicroce Giacobini J,Maeda K,Rohde M,Jäättelä M

    更新日期：2019-09-01 00:00:00

  • Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer.

    abstract：:Recently there have been explosive discoveries of new long noncoding RNAs (lncRNA) obtained by progress in the technology of second-generation sequencing. Genome scale analysis of transcriptome, in conjunction with studies on chromatin modifications at the epigenetic level, identified lncRNAs as a novel type of noncod...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章,评审

    doi：10.1158/1535-7163.MCT-18-0124

    authors： Zhang L,Peng D,Sood AK,Dang CV,Zhong X

    更新日期：2018-09-01 00:00:00

  • CCR5-Dependent Homing of T Regulatory Cells to the Tumor Microenvironment Contributes to Skin Squamous Cell Carcinoma Development.

    abstract：:Squamous cell carcinoma (SCC) is one of the most common human cancers worldwide. Recent studies show that regulatory T cells (Treg) have a critical role in the modulation of an antitumor immune response, and consequently the SCC development. Because the accumulation of Tregs at the tumor site is, in part, due to selec...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-17-0341

    authors： de Oliveira CE,Gasparoto TH,Pinheiro CR,Amôr NG,Nogueira MRS,Kaneno R,Garlet GP,Lara VS,Silva JS,Cavassani KA,Campanelli AP

    更新日期：2017-12-01 00:00:00

  • Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis.

    abstract：:Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy that frequently metastasizes and that overexpresses transforming growth factor-beta s (TGF-beta s). To determine whether TGF-beta s can act to enhance the metastatic potential of PDAC, PANC-1 human pancreatic cancer cells were transfected with an expressio...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Rowland-Goldsmith MA,Maruyama H,Matsuda K,Idezawa T,Ralli M,Ralli S,Korc M

    更新日期：2002-01-01 00:00:00

  • A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.

    abstract：:Mutations in ERK signaling drive a significant percentage of malignancies. LY3009120, a pan-RAF and dimer inhibitor, has preclinical activity in RAS- and BRAF-mutated cell lines including BRAF-mutant melanoma resistant to BRAF inhibitors. This multicenter, open-label, phase I clinical trial (NCT02014116) consisted of ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1158/1535-7163.MCT-19-0681

    authors： Sullivan RJ,Hollebecque A,Flaherty KT,Shapiro GI,Rodon Ahnert J,Millward MJ,Zhang W,Gao L,Sykes A,Willard MD,Yu D,Schade AE,Crowe K,Flynn DL,Kaufman MD,Henry JR,Peng SB,Benhadji KA,Conti I,Gordon MS,Tiu RV,Hong

    更新日期：2020-02-01 00:00:00

  • A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells.

    abstract：:Bifunctional antibody fusion proteins engaging effector T cells for targeted elimination of tumor cells via CD3 binding have shown efficacy in both preclinical and clinical studies. Different from such a polyclonal T-cell recruitment, an alternative concept is to engage only antigen-specific T-cell subsets. Recruitmen...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-16-0207

    authors： Schmittnaegel M,Hoffmann E,Imhof-Jung S,Fischer C,Drabner G,Georges G,Klein C,Knoetgen H

    更新日期：2016-09-01 00:00:00

  • miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer.

    abstract：:Breast cancer is a major public health problem all over the world, and the current treatment strategies are not potent enough for some patients, especially those with triple-negative breast cancer (TNBC). Recent studies have demonstrated that microRNAs (miRNA) play vital roles in the development of TNBC. In this study...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-14-0243

    authors： Tang H,Liu P,Yang L,Xie X,Ye F,Wu M,Liu X,Chen B,Zhang L,Xie X

    更新日期：2014-12-01 00:00:00

  • The TLR3 Agonist Inhibit Drug Efflux and Sequentially Consolidates Low-Dose Cisplatin-Based Chemoimmunotherapy while Reducing Side Effects.

    abstract：:The traditional maximum dose density chemotherapy renders the tumor patients not only the tumor remission but the chemotherapy resistance and more adverse side effects. According to the widely positive expression of Toll-like receptor (TLR)-3 in oral squamous cell carcinoma (OSCC) patients (n = 166), we here provided ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-16-0454

    authors： Ding L,Ren J,Zhang D,Li Y,Huang X,Ji J,Hu Q,Wang H,Ni Y,Hou Y

    更新日期：2017-06-01 00:00:00

  • GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.

    abstract：:EP-100 is a synthetic lytic peptide that specifically targets the gonadotropin-releasing hormone receptor on cancer cells. To extend the utility of EP-100, we aimed to identify effective combination therapies with EP-100 for ovarian cancer and explore potential mechanisms of this combination. A series of in vitro (MTT...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-18-0770

    authors： Ma S,Pradeep S,Villar-Prados A,Wen Y,Bayraktar E,Mangala LS,Kim MS,Wu SY,Hu W,Rodriguez-Aguayo C,Leuschner C,Liang X,Ram PT,Schlacher K,Coleman RL,Sood AK

    更新日期：2019-05-01 00:00:00

  • Inhibition of TRIP1/S8/hSug1, a component of the human 19S proteasome, enhances mitotic apoptosis induced by spindle poisons.

    abstract：:Mitotic spindle poisons (e.g., Taxol and vinblastine), used as chemotherapy drugs, inhibit mitotic spindle function, activate the mitotic spindle checkpoint, arrest cells in mitosis, and then cause cell death by mechanisms that are poorly understood. By expression cloning, we identified a truncated version of human TR...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-05-0126

    authors： Yamada HY,Gorbsky GJ

    更新日期：2006-01-01 00:00:00

  • A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.

    abstract：:Urokinase plasminogen activator (uPA) is a tumor-specific protease highly expressed in several types of solid tumors and rarely present on normal cells under physiologic conditions. Due to its high expression on metastatic tumors, several different strategies have been used to target the urokinase system. These have m...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-06-0315

    authors： Abi-Habib RJ,Singh R,Liu S,Bugge TH,Leppla SH,Frankel AE

    更新日期：2006-10-01 00:00:00

  • Novel glycosylated VEGF decoy receptor fusion protein, VEGF-Grab, efficiently suppresses tumor angiogenesis and progression.

    abstract：:Antiangiogenic therapies targeting VEGFA have been commonly used in clinics to treat cancers over the past decade. However, their clinical efficacy has been limited, with drawbacks including acquisition of resistance and activation of compensatory pathways resulting from elevated circulating VEGFB and placental growth...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-14-0968-T

    authors： Lee JE,Kim C,Yang H,Park I,Oh N,Hua S,Jeong H,An HJ,Kim SC,Lee GM,Koh GY,Kim HM

    更新日期：2015-02-01 00:00:00

  • Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention.

    abstract：:Several studies have identified silibinin as an anticarcinogenic agent. Recently, we showed that silibinin inhibits cell growth via G1 arrest, leading to differentiation of androgen-dependent human prostate carcinoma LNCaP cells (X. Zi and R. Agarwal, Proc. Natl. Acad. Sci. USA, 96: 7490-7495,1999). Here, we extend th...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Tyagi A,Agarwal C,Agarwal R

    更新日期：2002-05-01 00:00:00

  • Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.

    abstract：:Gefitinib (Iressa, ZD1839), a quinazoline tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR), is approved for patients with advanced non-small cell lung cancer (NSCLC) in several countries including Japan. However, the mechanism of drug sensitivity to gefitinib is not fully understood. ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Ono M,Hirata A,Kometani T,Miyagawa M,Ueda S,Kinoshita H,Fujii T,Kuwano M

    更新日期：2004-04-01 00:00:00

  • Phage Display-Derived Peptide-Based Dual-Modality Imaging Probe for Bladder Cancer Diagnosis and Resection Postinstillation: A Preclinical Study.

    abstract：:Bladder cancer is a common human malignancy. Conventional ultrasound and white-light cystoscopy are often used for bladder cancer diagnosis and resection, but insufficient specificity results in a high bladder cancer recurrence rate. New strategies for the diagnosis and resection of bladder cancer are needed. In this ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-18-0212

    authors： Peng L,Shang W,Guo P,He K,Wang H,Han Z,Jiang H,Tian J,Wang K,Xu W

    更新日期：2018-10-01 00:00:00

  • Uncommon tumors and exceptional therapies: paradox or paradigm?

    abstract：:Why does it seem that, repeatedly, when a new treatment with a striking effect is discovered in the cancer field, it is effective for a very rare cancer type? For example, groundbreaking therapeutic discoveries have been made for extremely uncommon malignancies such as hairy cell leukemia, chronic myelogenous leukemia...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-06-0674

    authors： Braiteh F,Kurzrock R

    更新日期：2007-04-01 00:00:00

  • MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.

    abstract：:Genomic analyses of squamous cell carcinoma (SCC) have yet to yield significant strategies against pathway activation to improve treatment. Platinum-based chemotherapy remains the mainstay of treatment for SCC of different histotypes either as a single-agent or alongside other chemotherapeutic drugs or radiotherapy; h...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-15-0062

    authors： Kong LR,Chua KN,Sim WJ,Ng HC,Bi C,Ho J,Nga ME,Pang YH,Ong WR,Soo RA,Huynh H,Chng WJ,Thiery JP,Goh BC

    更新日期：2015-07-01 00:00:00

  • Reactive oxygen species mediated apoptosis of esophageal cancer cells induced by marine triprenyl toluquinones and toluhydroquinones.

    abstract：:Marine invertebrates, algae, and microorganisms are prolific producers of novel secondary metabolites. Some of these secondary metabolites have the potential to be developed as chemotherapeutic agents for the treatment of a wide variety of diseases, including cancer. We describe here the mechanism leading to apoptosis...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-06-0760

    authors： Whibley CE,McPhail KL,Keyzers RA,Maritz MF,Leaner VD,Birrer MJ,Davies-Coleman MT,Hendricks DT

    更新日期：2007-09-01 00:00:00

  • Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells.

    abstract：:The androgen receptor (AR) is a key driver and therapeutic target in androgen-sensitive prostate cancer, castration-resistant prostate cancer (CRPC), and CRPC resistant to abiraterone and enzalutamide, two second-generation inhibitors of AR signaling. Because current AR inhibitors target a functioning C-terminal ligan...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-18-0432

    authors： Dong J,Wu Z,Wang D,Pascal LE,Nelson JB,Wipf P,Wang Z

    更新日期：2019-01-01 00:00:00

  • Inhibition of Mouse Breast Tumor-Initiating Cells by Calcitriol and Dietary Vitamin D.

    abstract：:The anticancer actions of vitamin D and its hormonally active form, calcitriol, have been extensively documented in clinical and preclinical studies. However, the mechanisms underlying these actions have not been completely elucidated. Here, we examined the effect of dietary vitamin D and calcitriol on mouse breast tu...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-15-0066

    authors： Jeong Y,Swami S,Krishnan AV,Williams JD,Martin S,Horst RL,Albertelli MA,Feldman BJ,Feldman D,Diehn M

    更新日期：2015-08-01 00:00:00

  • Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB.

    abstract：:Zoledronic acid, a third-generation bisphosphonate, has been shown to reduce cell migration, invasion, and metastasis. However, the effects of zoledronic acid on the epithelial-mesenchymal transition (EMT), a cellular process essential to the metastatic cascade, remain unclear. Therefore, the effects of zoledronic aci...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-12-0304

    authors： Schech AJ,Kazi AA,Gilani RA,Brodie AH

    更新日期：2013-07-01 00:00:00